Abstract Library

#3711 Evaluation of unreimbursed costs in the UK through utilisation of home administration of lanreotide autogel (LAN) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Homecare is an established delivery method utilised by the UK NHS. In the UK, patients with GEP-NETs on a stable dose of LAN can be trained for self or partner administration or can be administered by a homecare nurse. Both methods remove LAN related activity in an acute setting, negating costs to the provider. The National Tariff payment system is a set of prices to help the NHS deliver value to patients. The price, as set out in the 2022/23 National Tariff workbook, for a single professional follow-up endocrinology outpatient appointment is £101. The cost of this activity, as set out in the 2020/21 National Schedule of Costs, is £197. This represents a potential unreimbursed cost to the NHS of £96 per outpatient appointment.

Conference:

Presenting Author: Bolton R

Authors: Higgs K, Halpin C, Bolton R, Frankcom I,

Keywords: gastroenteropancreatic neuroendocrine tumor, lanreotide autogel, home administration, un-reimbursed costs,

#2837 Development and Initial Validation of a Brief Questionnaire to Assess Patient Satisfaction with Self-Injection of Lanreotide Autogel: Results During a Home Training Programme

Introduction: The long acting formulation of lanreotide autogel(LAN) can facilitate self-injection (SI) by patients or caregivers at home, avoiding visits to health centers. Training by nurses is required to ensure successful SI. Patient satisfaction(PS) is an important outcome of SI and home care programs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hernando J

Authors: Hernando J, Teulé A, Simó-Servat A, Serrano R, Venegas E,

Keywords: Lanreotide, Satisfaction, Home training,